Apr 17, 2023
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023    read more...
Apr 13, 2023
BeiGene Expands Presence in Latin America With Opening of Brazil Office    read more...
Mar 30, 2023
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity    read more...
Mar 21, 2023
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey    read more...
Feb 27, 2023
BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results    read more...
Feb 24, 2023
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference    read more...
Feb 24, 2023
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China    read more...
Feb 03, 2023
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care    read more...
Feb 01, 2023
BeiGene to Present at Upcoming Investor Conferences    read more...
Jan 19, 2023
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia    read more...
Jan 19, 2023
BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA    read more...
Jan 18, 2023
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List    read more...
Jan 17, 2023
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium    read more...
Jan 04, 2023
BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference    read more...
Dec 30, 2022
BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab    read more...
Dec 13, 2022
 BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH    read more...
Dec 09, 2022
BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors    read more...
Nov 22, 2022
BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022    read more...
Nov 17, 2022
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL)    read more...
Nov 15, 2022
BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care    read more...